Posted on 553
Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity.
Serving in key leadership roles on Aviceda’s Executive Leadership Team will be:
Mohamed Genead, MD, CEO & President,
David Callanan, MD, Chief Medical Officer,
Derek Kunimoto, MD, JD, Chief Operating Officer,
Michael Tolentino, MD, Chief Technology Officer, and
Christopher Scott, PhD, Chief Scientific Officer.
Global Healthcare Artificial Intelligent Market 2020 Share, Trend, Segmentation and Forecast to 2026 texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.